Lipid regulation using ezetimibe combined with simvastatin in patients with coronary heart disease

AIM: To explore the regulatory effect of ezetimibe combined with simvastatin on lipid and inflammatory cytokines in patients with coronary heart disease(CHD).METHODS: Sixty patients with CHD admitted to our hospital between May 2011 and September 2011 were randomly divided into two groups: treatment group and control group(30 patients/group).Ezetimibe(10 mg/day) combined with simvastatin(20 mg/day) was used in the treatment group and independent simvastatin(40 mg/day) was administered in the control group.Total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),hepatic function,renal function,and creatine kinase(CK) were examined,respectively,before administration and 4 weeks and 8 weeks after administration.RESULTS: Compared with baseline level,TC and LDL-C decreased in the two groups 4 weeks after administration(P0.05).After 8 weeks,these indicators decreased further in both groups(P0.01).Compared with those in control group,TC and LDL-C in treatment group significantly decreased after 8 weeks(P0.05).No significant differences of hepatic function,renal function and CK were found in both groups.CONCLUSION: Ezetimibe combined with simvastatin was shown to be more effective in decreasing serum lipid concentrations in patients with CHD.